+34 9340006100 -ext. 437807-info@nanbiosis.com

Posts on Jan 1970

The door is now open to a new nanoparticle-based treatment for chronic liver disease

– It is possible to achieve an administration method that improves the effectiveness and increases the safety of drugs for chronic liver disease?

-Yes, with nanoparticles!

– How?

To find an answer, was created the european project NANOSIM (Biodegradable nanoparticles of Simvastatin as new therapeutic tool for chronic liver disease financed in the Joint Transnational Call (2018) led by the Hospital Vall d´Hebron. A translational research proposed as an approach for its use in patients.

Until now, the only therapeutic option for patients is to eliminate the etiological agent (or the external promoter of damage), whether it is a virus, such as Hepatitis B, or a substance, such as alcohol. Once the agent is eliminated, only preventive treatment of the main associated complications can be carried out, but nothing to prevent or slow down the damage to the liver.

Now, the team behind NANOSIM project has published a study in the journal Pharmaceutics that opens the door to a treatment that specifically targets the sinusoidal endothelial cells of the liver, which are the first inducers of liver damage. The innovation is not a new drug, but a new delivery method that uses nanotechnology so that the drug acts directly on key liver cells.

The study has been led by María Martell, head of the Advanced Chronic Liver Diseases laboratory within the VHIR Liver Diseases group and with the collaboration of Ibane Abasolo, head of the VHIR Clinical Biochemistry, Drug Delivery and Therapy group. The researchers from both groups belong to the Network Biomedical Research Center (CIBER) in the area of Liver and Digestive Diseases (CIBEREHD) and Biomedicine, Biomaterial and Nanomedicine (CIBER-BBN), respectively. The U20 of the ICTS NANBIOSIS has also participated in the study.

Dr. Martell highlights the importance of advancing new and better treatments for cirrhosis: “Chronic liver diseases are the fifth cause of mortality in adults aged 50-70 years and cause 85% of liver transplants. Only in the territory European it is estimated that there are 29 million people affected”.

The research team focused on simvastatin, a drug used as an adjunctive therapy for cholesterol and which had been shown to have a protective function of endothelial cells, which are key to preventing the creation of liver fibrosis that causes liver inflammation. The problem is that oral or intravenous administration of the necessary dose causes a series of side effects, at the muscle and liver level, which limits its use. The goal of the research was to find a way to deliver the drug directly to the endothelial cells of the hepatic sinus without it being able to disperse to other parts of the body and causing unwanted side effects.

This active and specific targeting was achieved by binding polymeric micelles to peptides recognized by the surface marker CD32b, specific for liver endothelial cells. In this way, in in vivo models, a reduction in liver fibrosis was achieved without a significant increase in toxicity and, therefore, an effective and safe method to treat chronic liver diseases.

Dr. Abasolo, Director of NANBIOSIS U20 adds “Once that we have demonstrated the effectiveness of the technology to directly reach the sinus endothelial cells, a wide range of possible medications opens up with which we can use this nanotechnology to improve liver function.”

Article of reference:

Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells

Read More

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meetting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas.

  • On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience.
  • On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break).

Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting.

Moreover, at the “Posters & beers” session (Monday 6th: 6:00 p.m. – 7:00 p.m.) poster tours were organized where attendees could cast their vote for the best poster and use this one-on-one time with presenters to learn more, ask juicy questions and discuss their work. At 8:00 p.m., the awards ceremony took place for the best oral communication and best poster by young authors – for each area.

It was an impactful information sessions on research carried out by the groups of CIBER-BBN and CIBEREHD thematic areas.

The poster session is always a popular feature at CIBER-BBN Annual Meeting for acknowledgment NANBIOSIS units’ participation in the research carried out during the year. These are the works presented in 2023:

Targeted nanotoxin for the selective depletion of CXCR4+ cancer cells and immune cell recruitment in a colorectal cancer mouse model. Luis Miguel Carrasco-Díaz, Naroa Serna, Eric Voltà-Durán, Ugutz Unzueta, Esther Vázquez, Antonio Villaverde, Patricia Álamo, Lorena Alba-Castellón, Ramón Mangues. With participation of NANBIOSIS Units U1 Protein Production Platform (PPP) and U18 Nanotoxicology Unit . (Contact:

Improvement of the biodistribution of GLA enzyme by RGD-functionalized nanoGLA in a Fabry mouse model.
Zamira Vanessa Diaz Riascos, Marc Moltó Abad, Daniel Marijuan, Belen García Prats, Judit Tomsen Melero, Elisabet González Mira, Jose Luis Corchero, Andreu Soldevila, Miriam Royo, Alba Córdoba, Nora Ventosa, Guillem Pintos Morell, Simo Schwartz , Ibane Abasolo. With participation of the NANBIOSIS units U20 FVPR-In Vivo Experimental Platform and U6 Biomaterial Processing and Nanostructuring Unit. (Contact:

An auristatin-based nanoconjugate induces apoptosis and inhibits the bone marrow leukemia burden in an acute myeloid leukemia mouse model. Annabel Garcia-León, Julián I. Mendoza, Ariana Rueda, Luis Carlos Navas, Vanessa Huaca, Ugutz Unzueta, Jorge Sierra, Esther Vázquez, Antonio Villaverde, Ramon Mangues, Isolda Casanova. With participation of NANBIOSIS Units U1 Protein Production Platform (PPP) and U18 Nanotoxicology Unit. (Contact: agarciale@santpau.cat)

FVPR/U20-NANBIOSIS Service Platform: from the Synthesis and Characterization of Nanotechnology-based Therapies, to the in vitro and in vivo Preclinical Validation. Diana Rafael, Zamira V. Diaz Riascos, Belén García, Alejandra Palacios, Sandra Mancilla, Laura Garcia, Ibane Abasolo. Description of NANBIOSIS Unit 20 FVPR-In Vivo Experimental Platform. (Contact: diana.fernandes_de_so@vhir.org)

Non-Viral Vector Development for Gene Therapy in the Treatment of Congenital Liver Metabolic Diseases Lucía Enríquez Rodríguez, Isabel Carbonell Simón, Idoia Gallego Garrido, Virginia Nieto Romero, Iván Maldonado Pérez, Aida Garcia Torralba, Gustavo Puras Ochoa, Miruna Giurgiu, Jose Carlos Segovia Sanz, María García Bravo, Oscar Quintana Bustamante, José Luis Pedraz Muñoz. With participation of NANBIOSIS U10 Drug Formulation unit. (Contact: lucia.enriquez@ehu.eus)

X-ray Photoelectron Spectroscopy (XPS) Analysis of Nitrogen Environment in Small Extracellular Vesicle Membranes: A Potential Novel Technique with Application for Cancer Screening.
Ana Martín-Pardillos, María Sancho-Albero , Silvia Irusta , Víctor Sebastián , Vicente Luis Cebolla , Roberto Pazo-Cid , Pilar Martín-Duque , Jesús Santamaría. With participation of NANBIOSIS U9 Synthesis of Nanoparticles Unit. (Contact: a.martin_pardillos@unizar.es)

Nanoparticle-based approach for blood-brain-barrier crossing and glioblastoma treatment. Júlia German-Cortés, Raquel Herrero, Diana Rafael, Ibane Abasolo, Fernanda Andrade. With participation of NANBIOSIS Unit 20 FVPR-In Vivo Experimental Platform. (Contact: fernanda.silva@vhir.org)

Exploiting mammalian cells for recombinant protein production: an improved protocol for transient gene expression. Aida Carreño Fibla, Roger Fernández Palomeras, José Luis Barra, Rosa Mendoza Moreno, Mercedes Márquez Martínez, Neus Ferrer-Miralles, Antonio Villaverde Corrales, José Luis Corchero Nieto. With participation of NANBIOSIS Units U1 Protein Production Platform (PPP). (Contact:jlcorchero@ciber-bbn.es)

Surface characterization of a PLA/Qr/Mg biocomposite after in vitro degradation in m-SBF. Juan Manuel Casares-López, Margarita Hierro-Oliva, Verónica Luque-Agudo, Amparo M. Gallardo-Moreno, María Luisa González-Martín. With participation of Unit 16 Surface Characterization and Calorimetry Unit (Contact: mlglez@unex.es)

The poster session was an effective forum for the exchange of information and a means to communicate ideas

Read More

Open Position: Science Communicator for NANBIOSIS ICTS in Valencia

Deadline: 16/11/2023

If you are a Scientist and a passionate Communicator eager to develop your own ideas and strategy, keep reading!

The biomedicine consortium CIBER, is looking for a Ph.D. in science to develop the Communication Plan of the ICTS NANBIOSIS.

You will have the opportunity of working with top level researchers in the areal of biomaterials, bioingeniering and nanomedicine in a diverse and inclusive team working directly with the Coordinator of NANBIOSIS and the project manager team of CIBER-BBN

Applications must be filed at CIBER’s web portal untill November 16th.

We look for a Science Degree (Biology, Biotechnology, Biochemistry or similar), to work as Communication Manager of the ICTS NANBIOSIS, carrying out the design and execution of the ICTS Communication Plan. You will find all the details in the link of CIBER´s portal

The position requires good command of English and strong skills


NANBIOSIS is a Singular Scientific-Technical Infrastructure (ICTS) that supports biomedical research being able, for exemple, of developing a therapeutic agent and reaching its preclinical validation, taking advantage of the coordinated knowledge and experience of the main research groups in bioengineering, biomaterials and nanomedicine in Spain. It is composed by the Research Platforms of the “Consorcio Centro de Investigación Biomédica en Red, in ​​Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)”, the Infrastructure of Preclinical Testing and Development of Minimally Invasive Technologies of the “Centro de Cirugía de Mínima Invasión Jesús Usón (CCMIJU)” and the Nanoimaging unit of the “Instituto de Investigación Biomédica de Málaga IBIMA-Plataforma BIONAND).

Our main goals are:

1. Promote and consolidate the offer of the NANBIOSIS strategic services, which target advanced challenges in biomedical research: our Cutting-Edge Biomedical Solutions.

2. Promote the open and competitive access to NANBIOSIS services and, especially, to our strategic services.

3. Strengthen NANBIOSIS communication tools and enhance internationalization capabilities.

Help us transform the way our research and capacities connect with the science community and society.

Science communication matters!

Read More